Trial Profile
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Setrusumab (Primary) ; Zoledronic acid (Primary)
- Indications Osteogenesis imperfecta
- Focus Therapeutic Use
- Acronyms ASTEROID
- Sponsors Ultragenyx Pharmaceutical
- 09 Sep 2022 According to a Ultragenyx Pharmaceutical media release, data from this study will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR).
- 01 Oct 2021 According to a Mereo BioPharma Media Release, secondary endpoint data were presented at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting by Suzanne Jan de Beur.
- 01 Oct 2021 Results published in the Mereo BioPharma Media Release